VeriChip Corp. Outlines Current Applications & Potential Future Applications for its First-of-a-Kind Implantable RFID Implant...
07 7월 2009 - 9:30PM
Business Wire
VeriChip Corporation (�VeriChip� or the �Company�)
(NASDAQ:CHIP), a provider of radio frequency identification (RFID)
systems for healthcare and patient-related needs, today provided
additional comments regarding its VeriMed� Health Link patient
identification system following the recent passage of a bill by the
Pennsylvania House of Representatives banning forced microchip
implantation in humans, and also outlined its current and potential
future applications for its RFID implantable microchip. The VeriMed
Health Link system was cleared by the FDA in 2004 as a Class II
medical device and is the first and only implantable microchip
cleared by the FDA for patient identification.
The Company�s VeriMed Health Link system is the connection
between a patient and their personal health record. It provides
emergency room doctors and nurses with immediate access to vital
medical and emergency contact information, which will help them to
treat the patient rapidly, accurately and safely during an
emergency. Health Link utilizes a tiny microchip (similar in size
to a grain of rice), handheld scanner and a secure online database.
The Health Link microchip stores only a unique 16-digit
identification number and is injected just under the skin in the
rear upper portion of the right arm. When a Health Link member
presents in an emergency department unconscious, unresponsive or
confused, emergency medical personnel use the Health Link scanner
to retrieve the member�s identification number to access his or her
personal health record.
The Company has always focused on improving the health and
welfare of high-risk patients who chose its first-of-its-kind,
FDA-cleared technology, the VeriMed� Health Link system. As the
VeriMed Health Link system evolves from identification to other
applications including potential diagnosis and treatment, with
applications ranging from the glucose-sensing microchip to other
sensor applications and more, the Company envisions the full
development of its technology through various patents it holds. In
light of the current administration and its focus on personal
health records, the Company anticipates the continuing evolution of
its intellectual property and technology.
One example of the Company�s current technology in action is its
relationship with Alzheimer�s Community Care, based in West Palm
Beach, FL. More than 100 participating individuals, those suffering
from Alzheimer�s disease and other forms of dementia and their
caregivers, have received the Health Link implantable microchip to
provide emergency department staff easy access to those patients'
identification and medical information.
In November 2008, VeriChip purchased all intellectual property
related to implantable human RFID and sensor technologies
including, but not limited to, Patent No. 7,125,382 entitled
�Embedded Bio-Sensor System� from Digital Angel Corporation. That
patent is currently being utilized in connection with VeriChip�s
and its development partner�s, RECEPTORS LLC, efforts to jointly
develop a glucose-sensing device. VeriChip announced in December
2008 that the Phase I proof-of-concept program successfully
prepared prototype examples for both the glucose-selective binding
environment and the glucose-competitive signaling component. These
critical components were used to demonstrate the bench top format
application of the glucose-sensing system to the detection of
glucose levels. This demonstration is the proof-of-concept
foundation of the glucose-sensing system.
In May 2009, VeriChip, in conjunction with its development
partner, announced plans to develop surveillance and point-of-care
sensor systems that will efficiently detect and identify the
presence of a particular biological threat such as influenza virus,
Methicillin-resistant Staphylococcus aureus (MRSA) or other
illnesses. The companies published a white paper outlining the
development of �An Integrated Sensor System for the Detection of
Bio-Threats from Pandemics to Emerging Diseases to Bio-Terrorism,�
which is available at www.verichipcorp.com.
Silverman commented, �In November, I made a substantial
investment in this Company based on my belief in the technology,
its current applications and its potential in the future. As we
look to the future, we place significant value on our intellectual
property, including our implantable microchip, and the potential of
a glucose-sensing device and related sensor applications, to
address healthcare, identification and security needs around the
globe.�
VeriChip expects to hold a conference call at the end of July to
discuss recent corporate events and the future direction of the
Company. Additional details will be provided in a press release at
a later date.
About VeriChip
VeriChip Corporation, headquartered in Delray Beach, Florida,
has developed the VeriMed� Health Link System for rapidly and
accurately identifying people who arrive in an emergency room and
are unable to communicate. This system uses the first
human-implantable passive RFID microchip, cleared for medical use
in October 2004 by the United States Food and Drug Administration.
To complement its healthcare division, VeriChip Corporation
established VeriGreen Energy Corporation in March 2009 to focus and
invest in the clean and alternative energy sector.
For more information on VeriChip, please call 1-800-970-2447, or
e-mail info@verichipcorp.com. Additional information can be found
online at www.verichipcorp.com.
Statements about VeriChip�s future expectations, including
future revenues and earnings from the sale of its VeriMed Health
Link patient identification system and potential future
applications including a glucose-sensing RFID implantable microchip
and other applications, and all other statements in this press
release other than historical facts are �forward-looking
statements� within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Litigation Reform Act of 1995.
Such forward-looking statements involve risks and uncertainties and
are subject to change at any time, and VeriChip�s actual results
could differ materially from expected results. Additional
information about these and other factors that could affect the
Company�s business is set forth in the Company�s various filings
with the Securities and Exchange Commission, including those set
forth in the Company�s 10-K filed on February 12, 2009, under the
caption �Risk Factors.� The Company undertakes no obligation to
update or release any revisions to these forward-looking statements
to reflect events or circumstances after the date of this statement
or to reflect the occurrence of unanticipated events, except as
required by law.
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024